Document is current
Any future updates will be listed below
-
Authors
Costa, Dalila https://orcid.org/0000-0002-2430-9315
Trebicka, Jonel https://orcid.org/0000-0002-7028-3881
Ripoll, Cristina https://orcid.org/0000-0002-9704-4741
Moreau, Richard https://orcid.org/0000-0003-0862-403X
Jalan, Rajiv https://orcid.org/0000-0002-7747-4015
Reiberger, Thomas https://orcid.org/0000-0002-4590-3583
- License Information
-
More Information
Article History
Accepted: 17 July 2025
First Online: 29 September 2025
Competing interests
: J.T. has received speaking and/or consulting fees from Versantis, Gore, Boehringer-Ingelheim, Falk, Grifols, Genfit and CSL Behring. C.R. has received speaker fees from GORE, Falk Foundation and Bristol-Myers Squibb, and has acted as a consultant for Boerhinger-Ingelheim. C.R. receives funding from the DFG (Deutsche Forschung Gemeinschaft) project number 431667134 and the European Union Horizon 2020 research and innovation programme under grant agreement 101136299 ARTEMIS. R.J. is the founder of Yaqrit Discovery Limited, which owns Amalive Limited and Enterosorb Limited; is a co-founder of Cyberliver Limited and Hepyx Limited; has received payment for sponsored talks and grant reviews from Grifols; and has received consulting fees from Boehringer Ingelheim. T.R. has received grant support from Abbvie, Boehringer Ingelheim, Gilead, Intercept/Advanz Pharma, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens and W. L. Gore & Associates; speaking/writing honoraria from Abbvie, Echosens, Gilead, GSK, Intercept/Advanz Pharma, Pfizer, Roche, MSD, Siemens and W. L. Gore & Associates; consulting/advisory board fees from Abbvie, Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Intercept/Advanz Pharma, MSD, Resolution Therapeutics and Siemens; and travel support from Abbvie, Boehringer Ingelheim, Dr. Falk Pharma, Gilead and Roche. D.C. and R.M. declare no competing interests.
